VivoSeq
Ophthalmology

Neovascular Age-Related Macular Degeneration

8

Pipeline Programs↗

10

Active Trials↗

8

Companies Involved↗

Neovascular Age-related Macular Degeneration is an early-stage landscape with 8 programs across 8 companies. The most active players are Roche, AbbVie, Amgen. 1 therapy is approved with 5 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

39/100

Pipeline Velocity

19/100

Mech. Concentration

67/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

2 programs

Phase 3AbbVie logo

AbbVie

2 programs

Phase 3Amgen logo

Amgen

1 program

Phase 3Regeneron logo

Regeneron

1 program

Phase 3Novartis logo

Novartis

1 program

ApprovedSanofi logo

Sanofi

2 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

6programs
Small molecule233%
Monoclonal antibody233%
Protein / enzyme117%
Gene therapy117%

Modality classified for 73% of 11 pipeline programs.

Analysis

Trial Status

11

clinical trials

Recruiting8 · 73%
Active, not recruiting2 · 18%
Completed1 · 9%

Clinical Trials

Trial Activity

11 trials

A Phase 1/2 Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, and Efficacy of One-time Intravitreal Dose of SAR402663 in Participants With Neovascular Age-related Macular Degeneration
Recruiting·Sanofi logoSanofi·Preclinical·NCT06660667·66 enrolled
A Phase IV, Multicenter, Open-label Study to Assess Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS)
Recruiting·Roche logoRoche·Approved·NCT04853251·188 enrolled
A Randomized, Double-masked, Comparative Clinical Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 938 8 mg Versus EYLEA® HD (Aflibercept) Delivered Via Intravitreal Injection in Participants With Neovascular Age-related Macular Degeneration
Recruiting·Amgen logoAmgen·Phase 3·NCT07614776·304 enrolled
A Randomized, Controlled, Partially Masked, Phase 3b Study to Assess the Injection Burden, Efficacy, Safety, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec (ABBV-RGX-314) in a Real-World Context in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)
Recruiting·AbbVie logoAbbVie·Phase 3·NCT07007065·561 enrolled
A Phase III, Multicenter, Randomized, Visual Assessor-masked, Active-comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Chinese Patients With Neovascular Age-related Macular Degeneration
Recruiting·Roche logoRoche·Phase 3·NCT05562947·68 enrolled
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Portal)
Recruiting·Roche logoRoche·Phase 3·NCT03683251·1,000 enrolled
A Phase IIIb, Multicenter, Single-arm Study Assessing the Effectiveness, Safety and Patient Reported Outcomes of a 36-week Refill Exchange Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-related Macular Degeneration
Recruiting·Roche logoRoche·Phase 3·NCT06847542·250 enrolled
DATA-INSIGHT: Data Analysis for Treatment Assessment and Evaluation of New Sources for Evidence Generation in German Healthcare System
Recruiting·Bayer logoBayer·N/A·NCT07308639·50,000 enrolled
Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD
Active, not recruiting·JJaeb Center for Health Research·Phase 3·NCT05904028·603 enrolled
Real-World, Long-Term Data Collection to Gain Clinical Insights Into Faricimab (FaReal Study)
Active, not recruiting·Roche logoRoche·N/A·NCT06680817·850 enrolled
Safety and Effectiveness of ONS-5010 Compared to Lucentis® in Subjects With Neovascular Age-related Macular Degeneration; NORSE EIGHT
Completed·OOutlook Therapeutics, Inc.·Phase 3·NCT06190093·400 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)